Brokerages expect Zealand Pharma (NASDAQ:ZEAL) to post ($0.39) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Zealand Pharma’s earnings. Zealand Pharma posted earnings per share of ($0.15) during the same quarter last year, which indicates a negative year over year growth rate of 160%. The company is expected to report its next quarterly earnings results on Wednesday, May 16th.
On average, analysts expect that Zealand Pharma will report full year earnings of ($2.27) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of ($1.60) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Zealand Pharma.
Separately, Zacks Investment Research lowered shares of Zealand Pharma from a “buy” rating to a “hold” rating in a research report on Saturday, January 13th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $24.75.
Shares of ZEAL stock traded up $1.28 during mid-day trading on Monday, hitting $15.88. 5,633 shares of the stock traded hands, compared to its average volume of 23,800. The firm has a market cap of $448.97 and a price-to-earnings ratio of -10.73. Zealand Pharma has a 52-week low of $12.45 and a 52-week high of $20.37.
Institutional investors have recently made changes to their positions in the stock. OLD Mission Capital LLC purchased a new position in shares of Zealand Pharma in the 4th quarter valued at approximately $215,000. Jane Street Group LLC purchased a new position in shares of Zealand Pharma in the 3rd quarter valued at approximately $386,000. Fred Alger Management Inc. purchased a new position in shares of Zealand Pharma in the 4th quarter valued at approximately $544,000. Royce & Associates LP purchased a new position in shares of Zealand Pharma in the 3rd quarter valued at approximately $1,152,000. Finally, Susquehanna International Group LLP purchased a new position in shares of Zealand Pharma in the 3rd quarter valued at approximately $3,185,000. 9.07% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “-$0.39 Earnings Per Share Expected for Zealand Pharma (ZEAL) This Quarter” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/09/0-39-earnings-per-share-expected-for-zealand-pharma-zeal-this-quarter.html.
Zealand Pharma Company Profile
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
Get a free copy of the Zacks research report on Zealand Pharma (ZEAL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zealand Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma and related companies with MarketBeat.com's FREE daily email newsletter.